GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sumitomo Pharma Co Ltd (STU:DPM) » Definitions » Cyclically Adjusted PS Ratio

Sumitomo Pharma Co (STU:DPM) Cyclically Adjusted PS Ratio : 0.25 (As of Jun. 02, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Sumitomo Pharma Co Cyclically Adjusted PS Ratio?

As of today (2024-06-02), Sumitomo Pharma Co's current share price is €1.77. Sumitomo Pharma Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €7.20. Sumitomo Pharma Co's Cyclically Adjusted PS Ratio for today is 0.25.

The historical rank and industry rank for Sumitomo Pharma Co's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:DPM' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.25   Med: 1.47   Max: 3.84
Current: 0.25

During the past years, Sumitomo Pharma Co's highest Cyclically Adjusted PS Ratio was 3.84. The lowest was 0.25. And the median was 1.47.

STU:DPM's Cyclically Adjusted PS Ratio is ranked better than
92.2% of 744 companies
in the Drug Manufacturers industry
Industry Median: 2.085 vs STU:DPM: 0.25

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Sumitomo Pharma Co's adjusted revenue per share data for the three months ended in Mar. 2024 was €1.229. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €7.20 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Sumitomo Pharma Co Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Sumitomo Pharma Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sumitomo Pharma Co Cyclically Adjusted PS Ratio Chart

Sumitomo Pharma Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.33 1.79 1.06 0.66 0.33

Sumitomo Pharma Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.66 0.52 0.44 0.38 0.33

Competitive Comparison of Sumitomo Pharma Co's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sumitomo Pharma Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sumitomo Pharma Co's Cyclically Adjusted PS Ratio falls into.



Sumitomo Pharma Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Sumitomo Pharma Co's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1.77/7.2
=0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sumitomo Pharma Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Sumitomo Pharma Co's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.229/107.2000*107.2000
=1.229

Current CPI (Mar. 2024) = 107.2000.

Sumitomo Pharma Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 1.629 98.000 1.782
201409 1.610 98.500 1.752
201412 1.725 97.900 1.889
201503 1.782 97.900 1.951
201506 1.779 98.400 1.938
201509 1.882 98.500 2.048
201512 2.006 98.100 2.192
201603 1.975 97.900 2.163
201606 2.201 98.100 2.405
201609 2.084 98.000 2.280
201612 2.209 98.400 2.407
201703 2.144 98.100 2.343
201706 2.346 98.500 2.553
201709 2.196 98.800 2.383
201712 2.331 99.400 2.514
201803 2.150 99.200 2.323
201806 2.269 99.200 2.452
201809 2.121 99.900 2.276
201812 2.380 99.700 2.559
201903 2.253 99.700 2.422
201906 2.422 99.800 2.602
201909 2.404 100.100 2.575
201912 2.625 100.500 2.800
202003 2.660 100.300 2.843
202006 2.781 99.900 2.984
202009 2.583 99.900 2.772
202012 2.656 99.300 2.867
202103 2.357 99.900 2.529
202106 2.489 99.500 2.682
202109 3.157 100.100 3.381
202112 2.707 100.100 2.899
202203 2.466 101.100 2.615
202206 2.842 101.800 2.993
202209 2.828 103.100 2.940
202212 2.483 104.100 2.557
202303 1.676 104.400 1.721
202306 1.244 105.200 1.268
202309 1.228 106.200 1.240
202312 1.321 106.800 1.326
202403 1.229 107.200 1.229

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sumitomo Pharma Co  (STU:DPM) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Sumitomo Pharma Co Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Sumitomo Pharma Co's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sumitomo Pharma Co (STU:DPM) Business Description

Traded in Other Exchanges
Address
6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Sumitomo Pharma Co (STU:DPM) Headlines